Archimedes Tech SPAC Partners II Co. Ordinary Shares (ATII)vsChurchill Capital Corp XI (CCXI)
ATII
Archimedes Tech SPAC Partners II Co. Ordinary Shares
$10.64
-0.09%
FINANCIAL SERVICES · Cap: $314.84M
CCXI
Churchill Capital Corp XI
$12.32
-3.83%
FINANCIAL SERVICES · Cap: $746.38M
Smart Verdict
WallStSmart Research — data-driven comparison
CCXI leads profitability with a 0.0% profit margin vs 0.0%. CCXI earns a higher WallStSmart Score of 23/100 (F).
ATII
Avoid23
out of 100
Grade: F
CCXI
Avoid23
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% revenue growth
Smaller company, higher risk/reward
ROE of 3.6% — below average capital efficiency
0.0% margin — thin
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Comparative Analysis Report
WallStSmart ResearchBull Case : ATII
ATII has a balanced fundamental profile.
Bull Case : CCXI
CCXI has a balanced fundamental profile.
Bear Case : ATII
The primary concerns for ATII are Revenue Growth, Market Cap, Return on Equity.
Bear Case : CCXI
The primary concerns for CCXI are Revenue Growth, EPS Growth, Market Cap.
Key Dynamics to Monitor
CCXI is growing revenue faster at 0.0% — sustainability is the question.
CCXI generates stronger free cash flow (-157,581), providing more financial flexibility.
Monitor SHELL COMPANIES industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ATII scores higher overall (23/100 vs 23/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Archimedes Tech SPAC Partners II Co. Ordinary Shares
FINANCIAL SERVICES · SHELL COMPANIES · USA
Archimedes Tech SPAC Partners II Co. (ATII) is a special purpose acquisition company (SPAC) focused on merging with high-growth technology firms that present significant expansion potential. Leveraging a seasoned management team with extensive experience in the technology sector, ATII seeks to create synergies that drive operational efficiencies and enhance shareholder value. With a strategic emphasis on identifying and partnering with disruptive innovators in the fast-evolving tech landscape, Archimedes presents a compelling investment opportunity for institutional investors aiming to gain exposure to transformative technologies and emerging market trends.
Visit Website →Churchill Capital Corp XI
FINANCIAL SERVICES · SHELL COMPANIES · USA
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new drugs for inflammatory disorders, autoimmune diseases, and cancer in the United States. The company is headquartered in Mountain View, California.
Compare with Other SHELL COMPANIES Stocks
Want to dig deeper into these stocks?